aarkstore | 09/14/2009
Genentech, Inc. - Financial and Strategic Analysis Review Summary : Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacturing, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Major focus of Genentech is on three areas namely; oncology, immunology, and tissue
The Sacramento Business Journal (Free subscription) | 08/11/2009
Dako A/S said Tuesday it signed an agreement with Genentech Inc. to collaborate on cancer tests.
The San Francisco Business Times (Free subscription) | 08/11/2009
Genentech Inc. and Danish cancer test maker Dako will collaborate on regulatory submissions on two of Dako's stomach cancer assays.
bizjournals (Free subscription) | 08/11/2009
Dako A/S said Tuesday it signed an agreement with Genentech Inc. to collaborate on cancer tests.
Tell-It-Like-It-Is (Free subscription) | 08/04/2009
SAN FRANCISCO -Google Inc. Chief Executive Eric Schmidt has resigned from Apple Inc.'s board because of the companies' conflicting interests as competition between the one-time allies heats up.The split announced Monday comes just a few weeks after Google unveiled plans for a personal computer operating system that could siphon sales from Apple's Mac line and just a few days after the Federal Communications...
Daily Advance - Business (Free subscription) | 08/03/2009
WASHINGTON — Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration app...
San Fransisco Chronicle (Free subscription) | 08/03/2009
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug. Avastin is already approved to treat... Sponsored Topics: Genentech - US Food and Drug Administration - Bevacizumab - Cancer - Food and Drug Administration
Miami Herald (Free subscription) | 08/03/2009
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
kansascity.com (Free subscription) | 08/03/2009
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
San Diego Union (Free subscription) | 08/03/2009
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
Seattle Post-Intelligencer (Free subscription) | 08/03/2009
WASHINGTON -- Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
The East Bay Business Times (Free subscription) | 07/30/2009
A late-stage trial of Genentech Inc.’s eye drug Lucentis showed improved vision at six months for patients with macular edema.
The East Bay Business Times (Free subscription) | 07/02/2009
Genentech Inc. said a Phase III study of Lucentis in patients with swelling of the eye caused by branch retinal vein occlusion — a common cause of blindness — showed that the drug improved vision.
The Industry Standard (Free subscription) | 06/15/2009
"The pace here at Genentech is incredible," says David Fowler, a senior manager in the company's corporate IT unit. "Even in this economic downturn, we are a growth company." Growth at a company whose mission is high tech requires two major thrusts in IT: "innovation, and a focus on our development staff," Fowler says. "The two really go together. Our supportive...
The Sacramento Business Journal (Free subscription) | 06/10/2009
Bayhill Therapeutics won $25 million in cash and equity as part of a possible $350 million license agreement with Genentech Inc.
The last article published by a user on Genentech Inc. :
aarkstore | 09/14/2009
Genentech, Inc. - Financial and Strategic Analysis Review Summary : Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacturing, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Major focus of Genentech is on three areas namely; oncology, immunology, and tissue...
Videos